Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p <0.05). Women with LVH had a higher prevalence of concentric hypertrophy than men (46% vs 29%, p = 0.0003). Logistic regression analysis demonstrated that female gender (odds ratio [OR] 2.80, p <0.0001), age (OR 1.03 per year, p <0.001), hypertension (OR 2.30, p <0.001), diabetes (OR 1.62, p = 0.004), and previous MI (OR 1.96, p = 0.001) were independently associated with LVH. In conclusion, patients with NVAF have a high prevalence of LVH, which is related to female gender, older age, hypertension, and previous MI. These patients are at high thromboembolic risk and deserve a holistic approach to cardiovascular prevention.

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation / Marra, ALBERTO MARIA; Tassone, Eliezer Joseph; De Vuono, Stefano; Corrao, Salvatore; Gobbi, Paolo; Perticone, Francesco; Corazza, Gino Roberto; Basili, Stefania; Lip, Gregory Y. H; Violi, Francesco; Raparelli, Valeria; Proietti, Marco. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - STAMPA. - 116:6(2015), pp. 877-882. [10.1016/j.amjcard.2015.05.060]

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

MARRA, ALBERTO MARIA;BASILI, Stefania;VIOLI, Francesco;RAPARELLI, Valeria;PROIETTI, Marco
2015

Abstract

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p <0.05). Women with LVH had a higher prevalence of concentric hypertrophy than men (46% vs 29%, p = 0.0003). Logistic regression analysis demonstrated that female gender (odds ratio [OR] 2.80, p <0.0001), age (OR 1.03 per year, p <0.001), hypertension (OR 2.30, p <0.001), diabetes (OR 1.62, p = 0.004), and previous MI (OR 1.96, p = 0.001) were independently associated with LVH. In conclusion, patients with NVAF have a high prevalence of LVH, which is related to female gender, older age, hypertension, and previous MI. These patients are at high thromboembolic risk and deserve a holistic approach to cardiovascular prevention.
2015
Age Distribution; Aged; Aged, 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)
01 Pubblicazione su rivista::01a Articolo in rivista
Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation / Marra, ALBERTO MARIA; Tassone, Eliezer Joseph; De Vuono, Stefano; Corrao, Salvatore; Gobbi, Paolo; Perticone, Francesco; Corazza, Gino Roberto; Basili, Stefania; Lip, Gregory Y. H; Violi, Francesco; Raparelli, Valeria; Proietti, Marco. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - STAMPA. - 116:6(2015), pp. 877-882. [10.1016/j.amjcard.2015.05.060]
File allegati a questo prodotto
File Dimensione Formato  
Proietti_Frequency_2015.pdf

solo gestori archivio

Note: articolo principale
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 307.83 kB
Formato Adobe PDF
307.83 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/791947
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 24
social impact